Germany’s GKV-SV targets to increase medicines’ spending ceiling by 4.6% in 2021
Blogpost created by Dimitra S. Sotou, Client Solutions Lead, Pricing & Market Access
As opposed to the rest of key EU payers focusing on cost containment strategies for 2021, the German umbrella payer group GKV-Spitzenverband (GKV-SV) has announced to be targeting a +4.6% increase in national medicines expenditure within 2021 under an agreement reached with the National Association of Statutory Health Insurance Physicians (KBV).
The spending adjustments have occurred to account for “the use of innovative drugs” (+4.6%), with a price reductions of -0.2% and a shift between service areas of community physicians and hospitals of +0.2%, according to the agreement dated 1 October.
So far, no further details on the innovative drugs have been provided in the agreement. The agreement, which is negotiated annually, aims to regulate doctors’ prescriptions and forms the basis for regional objectives which are then fixed between the statutory health insurance (GKV) and the 16 community-based doctors’ regional associations (KV).
According to the agreement, the additional costs through pharmacy delivery to patients and savings through a temporarily reduced value-added tax (VAT) rate are not included in the calculations neither for 2020 nor 2021 as these were considered as one-off effects due to the current #COVID pandemic.
Thinking of the impact this increase can have onto pricing & access landscape, GPI experts expect:
- Increasing room for expenditure, surely creates incentives for innovative medicines’ manufacturers to maintain Germany as their go-to market for successful launch in Europe; therefore, we can expect a potential spike in new product launches in Germany within 2021. In parallel, GBA increases data requirements for price & reimbursement negotiations to keep the cost-benefit balance
- Due to the focus on innovative therapies, it is likely to observe further establishment of funds for high-cost therapies such as cell & gene therapies or orphan medicines. This can also contribute to higher likelihood of those costly therapies to stay on market post-AMNOG negotiations and for the longer run
- Other EU markets could potentially start picking up Germany’s approach on medicines’ spending management and tactics; however, other economic factors also come into play
Will the above-mentioned measures also have a positive impact on patient access to innovative treatments after all or are there other influencing factors that still impose hurdles? This remains to be seen…
To learn more about how we support bio-pharma keep up to date with the latest policy, regulatory and pricing & access updates please reach out at email@example.com
Keep track of all the latest changes with GPI pulse
GPI’s extensive platform, GPI PulseTM, stores policy, pricing, reimbursement, IRP matrix, and regulatory data in more than 96 countries. If you would like to keep up to date of all the latest regulations and policy along with historical and current pricing & access updates, please fill in your details below and a member of our expert team will get back to you.
We are leading the way forward with analytical and platform driven price and access solutions – to a future where reliable data insights empower confident strategic decision-making and drive meaningful change in the life sciences market.
Quick access to quality insights is the key to understanding global payer needs and setting the right prices at pace. And, when it comes to getting therapies to patients fast, consistently accurate insights are critical.
GPI pulse and GPI HORIZON, supported by experienced consultants use robust validated methodology to provide high quality, curated insights on global prices, market access decisions, asset evaluation, value perception and payer behaviour.
We provide an agile, data-driven, and future-focused perspective to pricing and market access. As your innovation partner, we will help you make the most of your insights to build strategies, optimise operations and identify market opportunities. With the right tools, insights, and know-how, you will make confident decisions to power the future of your business and shape the evolving biopharma landscape.